Published 2019-11-15
license
Article of Review (before OJS)

HIV, dyslipidemias and perspectives of its evolution

DOI: https://doi.org/10.22490/24629448.3637
Hugo Mendieta Zerón
Angela Montenegro Cárdenas
Joel Alberto Vargas Hernández
Araceli Consuelo Hinojosa Juárez

With the advent of antiretroviral therapy (ART), infection with the human immunodeficiency virus (HIV) has become a chronic disease with major metabolic complications more pronounced than in the general population. While there is no vaccine
to eradicate infection rates and there is no cure for this pandemic, it should be more incisive in controlling comorbidities, among which alterations in the lipid profile stand out as they increase cardiovascular risk.

keywords: human immunodeficiency virus infection, antiretroviral therapy, lipid profile, cardiovascular risk
license
How to Cite
Mendieta Zerón, H., Montenegro Cárdenas, A., Vargas Hernández, J. A. ., & Hinojosa Juárez, A. C. (2019). HIV, dyslipidemias and perspectives of its evolution. NOVA Biomedical Sciences Journal, 17(32), 83-93. https://doi.org/10.22490/24629448.3637
Almétricas
Metrics
File downloads
147
Jan 2020Jul 2020Jan 2021Jul 2021Jan 2022Jul 2022Jan 2023Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 20265.0
|

PRIVACY STATEMENT: In accordance with the Personal Data Protection Law (Law 1581 of 2012), the names and email addresses managed by Revista NOVA will be used exclusively for the purposes stated by this journal and will not be made available for any other purpose or to any other individual. Manuscripts submitted to the publication are only accessible to the editorial team and external peer reviewers.

Design and implemented by